From the Guidelines
Solriamfetol is not recommended for treating ADD/ADHD symptoms as it is not FDA-approved for this condition and its effects are more targeted toward promoting wakefulness rather than improving executive function and attention regulation. The medication is specifically approved for treating excessive daytime sleepiness in narcolepsy and obstructive sleep apnea 1. According to the evidence, stimulants such as methylphenidate or amphetamine-based medications, and non-stimulants like atomoxetine, guanfacine, or viloxazine are the preferred treatment options for ADD/ADHD symptoms 1. These medications have been extensively studied and have established dosing protocols and efficacy data.
Some key points to consider when treating ADD/ADHD symptoms include:
- The use of stimulants as first-line therapy and non-stimulants as second-line therapy 1
- The importance of individualizing treatment based on factors such as severity of symptoms, presence of comorbidities, and patient preferences 1
- The need for regular assessment of medication adherence and potential issues in adherence 1
- The preference for once-daily dosing over twice-daily dosing to improve medication adherence 1
It is essential to consult with a healthcare provider who can properly diagnose the condition and recommend appropriate treatment options based on specific symptoms and medical history. The healthcare provider can help determine the best course of treatment and ensure that the patient receives the most effective and safe treatment for their ADD/ADHD symptoms.
From the Research
Solriamfetol and ADHD Symptoms
- Solriamfetol may be a novel and effective treatment for the management of ADHD in adults, as shown in a double-blind placebo-controlled pilot study 2.
- The study found that individuals on solriamfetol treatment experienced significant improvements in total AISRS scores and had a greater proportion of individuals meeting the a priori-defined treatment response compared to those on placebo 2.
- Solriamfetol was also found to be well tolerated, with no significant effect on mean heart rate, systolic blood pressure, or diastolic blood pressure 2.
Mechanism of Action
- Solriamfetol is a norepinephrine/dopamine dual reuptake antagonist, which may contribute to its wake-promoting effects and potential benefits in treating ADHD symptoms 3, 4, 5.
- The mechanism of action of solriamfetol involves binding to dopamine and norepinephrine transporters and inhibiting reuptake of dopamine and norepinephrine, which may help improve symptoms of excessive daytime sleepiness and ADHD 4, 5.
Comparison to Other Treatments
- Current pharmacological treatments for ADHD include stimulant and nonstimulant medications, which have been shown to be effective in treating ADHD symptoms but may have significant adverse outcomes or side effects 6.
- Solriamfetol may offer a safe and effective alternative option for clinical providers treating excessive daytime sleepiness and ADHD, with a favorable pattern of effects and tolerability 2, 3, 5.